格隆汇9月3日｜梅西百货(M.US)盘前直线拉升，大涨超10%。消息面上，梅西百货第二季度净销售额为 48.1亿美元，市场预期为47.1亿美元；毛利率为39.7%，市场预期为39.5%。梅西百货预计财年净销售额 为211.5亿至214.5亿美元，此前预期为210亿至214亿美元；预计财年调整后每股收益为1.70至2.05美元， 此前预期为1.60至2美元，市场预期为1.81美元；预计第三季度净销售额将达到45亿美元至46亿美元，此 前预期为44.8亿美元。 ...

Group 1 - The core viewpoint of the article highlights Macy's strong second-quarter performance, with net sales of $4.81 billion, exceeding market expectations of $4.71 billion [1] - The gross margin for the second quarter was reported at 39.7%, slightly above the market expectation of 39.5% [1] - Macy's has revised its fiscal year net sales forecast to a range of $21.15 billion to $21.45 billion, up from the previous estimate of $21 billion to $21.4 billion [1] Group 2 - The company anticipates adjusted earnings per share for the fiscal year to be between $1.70 and $2.05, an increase from the prior forecast of $1.60 to $2.00, while the market expectation stands at $1.81 [1] - For the third quarter, Macy's expects net sales to reach between $4.5 billion and $4.6 billion, compared to the previous expectation of $4.48 billion [1]

Macy’s raised its annual outlook and reported its best comparable sales growth in 12 quarters, the latest signs that consumers are still spending despite concerns about inflation and tariffs https://t.co/u0ClEXqolu ...

Exhibit 99.1 Macy's, Inc. Reports Second Quarter 2025 Results Macy's, Inc. net sales and Adjusted diluted EPS exceeded guidance Macy's, Inc. delivered best comparable sales growth in 12 quarters Macy's go-forward business achieved comparable sales growth driven by Reimagine 125 locations Bloomingdale's and Bluemercury again delivered comparable sales growth 1 2 NEW YORK—September 3, 2025— Macy's, Inc. (NYSE: M) today reported financial results for the second quarter of 2025 and raised its annual net sales a ...

Earnings Report - Macy's, Inc. is set to release its fourth-quarter earnings results on September 3, with analysts expecting earnings of 19 cents per share, a decrease from 53 cents per share in the same period last year [1] - The anticipated quarterly revenue is $4.7 billion, down from $4.94 billion a year earlier [1] - The company's board declared a regular quarterly dividend of 18.24 cents per share on August 22 [1] Stock Performance - Macy's shares increased by 2% to close at $13.49 on Tuesday [2] - Analysts have provided various ratings and price targets for Macy's stock, reflecting differing outlooks on the company's performance [2] Analyst Ratings - Telsey Advisory Group maintained a Market Perform rating with a price target of $14 [7] - JP Morgan maintained a Neutral rating and raised the price target from $12 to $16 [7] - Citigroup kept a Neutral rating and increased the price target from $11 to $12 [7] - Morgan Stanley maintained an Equal-Weight rating but reduced the price target from $14 to $12 [7] - Goldman Sachs downgraded the stock from Buy to Neutral and cut the price target from $17 to $12 [7]

Group 1 - The U.S. consumers are facing a new wave of price increases as companies from food giants to hardware chains warn that tariff costs are being passed on to retail prices [1][2] - Major retailers like Walmart, Target, and Best Buy have indicated that tariff-related price hikes are gradually reflected in the costs of grocery items, home goods, and electronics [1] - J.M. Smucker warned of a 22% drop in coffee profits due to tariffs, leading to further price increases [1] - Hormel Foods noted a sharp rise in commodity input costs after its quarterly performance fell short of expectations, resulting in a 12% drop in its stock price [1] - A recent ruling by a federal appeals court deemed most of Trump's global import tariffs unconstitutional, adding uncertainty to future costs for retailers and consumers [1] Group 2 - The former CEO of Gap expressed that the current situation is beyond control, indicating that businesses cannot determine the relationship between product costs, retail pricing, and profit margins [2] - Retail executives warned that more price increases are imminent as new inventory is procured at higher costs [2] - Walmart's CEO mentioned that the company is trying to maintain low prices as long as possible, but costs are expected to continue rising into the third and fourth quarters [2] - The economic pressure is forcing retailers to weigh how much cost can be absorbed and how much will inevitably be passed on to consumers [2] - A consumer confidence survey showed a nearly 6% decline in August compared to July, with inflation expectations rising from 4.5% to 4.8% [2] Group 3 - Consumer behavior in the U.S. is changing, with households across income levels becoming more selective about where and how they spend [3] - Whirlpool's CEO noted that consumers are starting to purchase lower-end products, while Procter & Gamble observed a slight downgrade in brand preferences [3] - The concept of "alternative consumption" is emerging, where consumers opt for cost-effective substitutes rather than purely downgrading [3] - Retailers like TJX, Ross, and Marshall's are benefiting as consumers seek lower-priced brand items [3]

Financial Data and Key Metrics Changes - The company recorded a consolidated pro forma turnover of approximately $1,570 million, marking a 20% increase compared to the same period in 2024 [5] - Pro forma EBITDA advanced by 21%, reaching around $234 million, resulting in a margin of 16.1% [11] - Gross sales increased by 20.3%, reaching around $1,670 million, while operating profit increased by 17.7% to approximately $92.3 million [11] - Pro forma net loss was reported at $4.2 million due to significant foreign exchange losses [11][18] Business Line Data and Key Metrics Changes - Clinics accounted for 37% of total sales, with a 20% growth driven by a 13% rise in the number of visits and a 6% increase in average fees [13] - Hospitals represented about 28% of total sales, growing by 38% due to increased patient numbers and higher average fees [15] - Laboratories accounted for 11% of total sales, posting an 18% year-on-year growth driven by a 21% increase in lab tests performed [15] - Corporate accounts remained largely flat, with a 1.2% decline in subscriptions offset by a 0.9% increase in average fees [16] Market Data and Key Metrics Changes - The dental services market contracted, with a 5.5% decline in sales, attributed to increased competition and market dynamics [14] - The pharmacy segment grew by 13%, driven by a 22% increase in average spend per client [16] - The overall market for medical services is influenced by purchasing power, particularly for elective services [17] Company Strategy and Development Direction - The company is focusing on strategic investments in technology and innovation, particularly in robotic surgery and AI integration [6][10] - There is a commitment to expanding genetic testing and sequencing projects to enhance access to personalized medicine [9][11] - The company plans to maintain a low capital expenditure approach in the short term, prioritizing operational efficiency [10][21] Management's Comments on Operating Environment and Future Outlook - Management expects to maintain a stable trajectory while adapting to the evolving macroeconomic environment [9] - The company is closely monitoring potential impacts on purchasing power due to recent fiscal measures [9][17] - There is confidence in achieving budget targets for the full year, despite challenges from foreign exchange losses [38] Other Important Information - The company completed several acquisitions to strengthen its market position, including RoutineMed Group and All Clinic [6] - A significant investment of over €2 million was made in diagnostic infrastructure, enhancing the company's capabilities [8] - The net debt to pro forma EBITDA ratio remains stable at 3.72% as of June 2025 [18][19] Q&A Session Summary Question: What is the negative EBITDA from new hospital units and their breakeven timeline? - Management indicated that two large hospitals are close to breakeven, with expectations for positive results by the end of the year [22][23] Question: What is the estimated impact of VAT on costs? - The estimated impact of a 2% to 3% VAT increase is around €2 million per year, which is not considered significant [26][27] Question: What are the expectations for capital expenditures? - Capital expenditures are expected to remain low, with no significant investments planned for the third or fourth quarters [28][30] Question: How will rising energy costs affect the company? - Management does not foresee a major impact from rising energy costs, estimating a potential annual impact of €1 to €2 million [35][36] Question: What is the outlook for personnel expenses and public sector salary caps? - Recent government measures are expected to positively impact personnel expenses, with more doctors from the public sector willing to negotiate [42] Question: How does management plan to address currency risk? - Management is actively monitoring currency risks and has strategies in place to mitigate potential impacts [45][46]

Financial Data and Key Metrics Changes - The company recorded a consolidated pro forma turnover of approximately $1,570 million, representing a 20% increase compared to the same period in 2024 [5] - Pro forma EBITDA increased by 21%, reaching around $234 million, with a margin of 16.1% [11] - Gross sales increased by 20.3%, reaching around $1,670 million, while operating expenses rose by 10.9% to approximately $1,360 million [11] - The pro forma net loss was reported at $4.2 million, influenced by a foreign exchange loss of around $83 million [11][21] Business Line Data and Key Metrics Changes - Clinics accounted for 37% of total sales, with a 20% growth driven by a 13% rise in the number of visits and a 6% increase in average fees [13] - Hospitals represented about 28% of total sales, growing by 38% due to increased patient numbers and investments in technology [15] - Laboratories accounted for 11% of total sales, posting an 18% year-on-year growth, driven by a 21% increase in lab tests performed [16] Market Data and Key Metrics Changes - The corporate segment accounted for 9.75% of total sales, remaining largely flat compared to the previous year, with a 1.2% decline in subscriptions offset by a 0.9% increase in average fees [17] - The pharmacy segment represented 2.4% of total sales, with revenues growing by 13% due to a 22% increase in average spend per client [18] Company Strategy and Development Direction - The company is focusing on strategic investments in technology and innovation, particularly in robotic surgery and AI integration [6][9] - There is a commitment to expanding genetic testing capabilities, with an initial investment of €3 million for advanced sequencing technology [8] - The company plans to maintain a stable trajectory while adapting to the evolving macroeconomic environment, with a focus on operational efficiency [9][10] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining a stable net debt to pro forma EBITDA ratio, despite challenges from foreign exchange fluctuations [22] - The company is preparing for various scenarios due to macroeconomic challenges, including potential impacts from VAT increases [20] - Management anticipates that new hospital units will reach breakeven by the end of the year, contributing positively to overall performance [26][28] Other Important Information - The company completed several acquisitions to strengthen its market position, including RoutineMed Group and All Clinic [6] - Capital expenditures for the second half of the year are expected to remain low, with no significant investments planned [23] Q&A Session Summary Question: What is the current negative EBITDA from new hospital units and their breakeven timeline? - Management indicated that two large hospitals are close to breakeven, with expectations for positive results by mid-year [25][26] Question: What is the estimated impact of VAT increases on costs? - The estimated impact of a 2% to 3% VAT increase is around €2 million per year, which is not considered significant [29][30] Question: What are the expectations for capital expenditures in the near term? - Management confirmed that capital expenditures will be low, with no large investments planned for at least the third quarter [31][32] Question: How are rising energy costs affecting the company? - Management stated that rising energy costs are not expected to have a major impact, estimating a potential annual effect of €1 to €2 million [37][38] Question: What is the outlook for the full year in line with second-quarter results? - Management aims to fulfill the budget presented earlier in the year, despite challenges from foreign exchange rates [40][41]

Financial Data and Key Metrics Changes - The company recorded a consolidated pro forma turnover of approximately $1,570 million, representing a 20% increase compared to the same period in 2024 [5] - Pro forma EBITDA increased by 21%, reaching around $234 million, with a margin of 16.1% [11] - Gross sales increased by 20.3%, reaching around $1,670 million, while operating expenses rose by 10.9% to approximately $1,360 million [11] - The pro forma net loss was reported at $4.2 million, influenced by a foreign exchange loss of around $83 million [11][21] Business Line Data and Key Metrics Changes - Clinics accounted for 37% of total sales, with a 20% growth driven by a 13% rise in the number of visits and a 6% increase in average fees [13] - Hospitals represented about 28% of total sales, growing by 38% due to increased patient numbers and investments in technology [15] - Laboratories accounted for 11% of total sales, posting an 18% year-on-year growth driven by a 21% increase in lab tests performed [16] - Corporate accounts remained flat, with a 1.2% decline in subscriptions offset by a 0.9% increase in average fees [17] Market Data and Key Metrics Changes - The dental services market contracted, with a 5.5% decline in sales, attributed to increased competition and market dynamics [14] - The company noted that the market for elective medical services may be affected by changes in purchasing power due to recent fiscal measures [9] Company Strategy and Development Direction - The company is focusing on strategic investments in technology and innovation, particularly in robotic surgery and AI integration [7][10] - There is a commitment to expanding genetic testing capabilities, with an initial investment of €3 million for advanced sequencing technology [9] - The company plans to maintain a stable trajectory while adapting to the evolving macroeconomic environment, with a cautious approach to capital expenditures [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the performance of new hospital units, expecting them to reach breakeven by the end of the year [25][26] - The company is closely monitoring the impact of rising energy costs and potential government measures on purchasing power [37][39] - Management aims to fulfill the budget presented to investors and is optimistic about operational improvements despite foreign exchange losses [40][52] Other Important Information - The company completed several acquisitions to strengthen its market position, including RoutineMed Group and All Clinic [6] - Capital expenditures for the second half of the year are expected to remain low, with no significant investments planned [23][32] Q&A Session Summary Question: What is the negative EBITDA from new hospital units and their breakeven timeline? - Management indicated that two large hospitals are close to breakeven, with expectations for positive results by mid-year [25][26] Question: What is the estimated impact of VAT increases on costs? - The estimated impact of a 2% to 3% VAT increase is around €2 million per year, which is not considered significant [29][30] Question: What are the expectations for capital expenditures? - Management confirmed that capital expenditures will be low, with no large investments planned for the third or fourth quarters [31][32] Question: How will rising energy costs affect the company? - Management stated that the impact of rising energy costs is minimal, estimating a potential annual impact of €1 to €2 million [37][38] Question: What is the outlook for the full year results? - Management aims to fulfill the budget presented earlier and is optimistic about operational performance despite challenges [40][41]

Financial Performance - The Group achieved a consolidated pro-forma turnover of RON 1.57 billion in H1 2025, a 20.3% increase compared to H1 2024 [19] - Pro-forma EBITDA increased by 21.2% to RON 234.2 million, with a margin of 16.1% [34] - IFRS Revenues recorded a solid 20% increase, with 16.2% driven by organic growth [50] - Net cash from operating activities declined by 41% compared to the same period last year [60] Acquisitions and Investments - The Group finalized the acquisition of Routine Med Group in Tulcea in February [21] - A majority stake in All Clinic in the Republic of Moldova was acquired in March [21] - The acquisition of Medstar Clinic Group in Cluj-Napoca was announced in June, with 2024 revenues of approximately RON 32 million [22] - The company launched the first AI assistant integrated into its mobile app [25] - The company enhanced its diagnostic infrastructure with the 2nd automated laboratory line in the Group, with an investment of over EUR 2 million [26] - The company acquired the Illumina sequencing technology with an initial investment of EUR 3 million [27] Operational KPIs - Hospitals revenue increased by 37.8% to RON 437.787 million [50] - Clinics revenue increased by 20.3% to RON 586.623 million [50] - Laboratories revenue increased by 18.4% to RON 172.790 million [50]